Search results
Showing 361 to 375 of 529 results for drug monitoring
This is the user guide for submission of evidence to the National Institute for Health and Care Excellence (NICE) as part of the single technology appraisal and highly specialised technologies evaluations process. It explains what information NICE requires and the format in which it should be presented
Evidence-based recommendations on vemurafenib (Zelboraf) for treating advanced BRAF V600-positive malignant melanoma in adults.
Evidence-based recommendations on blinatumomab (Blincyto) with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive minimal residual disease-negative B-cell precursor acute lymphoblastic leukaemia in adults.
Vedolizumab for treating moderately to severely active Crohn's disease after prior therapy (TA352)
Evidence-based recommendations on vedolizumab (Entyvio) for previously treated moderately to severely active Crohn’s disease in adults.
Alitretinoin for the treatment of severe chronic hand eczema (TA177)
Evidence-based recommendations on alitretinoin (Toctino) for treating severe chronic hand eczema in adults.
Evidence-based recommendations on pembrolizumab (Keytruda) with lenvatinib (Lenvima) for treating advanced or recurrent endometrial cancer in adults.
Ozanimod for treating relapsing–remitting multiple sclerosis (TA706)
Evidence-based recommendations on ozanimod (Zeposia) for treating relapsing–remitting multiple sclerosis in adults with clinical or imaging features of active disease.
This quality standard covers the organisation and delivery of emergency and acute medical care in the community and in hospital. It covers adults (16 and over) who seek, or are referred for, emergency NHS care for a suspected or confirmed acute medical emergency. It describes high-quality care in priority areas for improvement.
View quality statements for QS174Show all sections
Sections for QS174
Evidence-based recommendations on peginterferon alfa (Pegasys; ViraferonPeg) and ribavirin (Copegus) for treating chronic hepatitis C in children and young people.
Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine (TA535)
Evidence-based recommendations on lenvatinib (Lenvima) and sorafenib (Nexavar) for progressive, locally advanced or metastatic differentiated thyroid cancer in adults who have had radioactive iodine.
Self-harm: assessment, management and preventing recurrence (NG225)
This guideline covers assessment, management and preventing recurrence for children, young people and adults who have self-harmed. It includes those with a mental health problem, neurodevelopmental disorder or learning disability and applies to all sectors that work with people who have self-harmed.
NICE has developed a Medtech Innovation Briefing (MIB) on the Space GlucoseControl system for managing blood-glucose in critically ill patients in intensive care
AcQMap for mapping the heart atria to target ablation treatment for arrhythmias (MIB246)
NICE has developed a medtech innovation briefing (MIB) on AcQMap for mapping the heart atria to target ablation treatment for arrhythmias .
Evidence-based recommendations on normothermic extracorporeal preservation of hearts for transplant after brainstem death. This technique is used to store a donor heart for longer before being transplanted.
This guideline covers diagnosis and management of thyroid cancer in people aged 16 and over. It aims to reduce variation in practice and increase the quality of care and survival for people with thyroid cancer.